A single-blind randomized controlled trial comparing Aprepitant plus (Granisetron)1st 5-HT3 receptor antagonist and Palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies including CBDCA in the gynecology cancer patients. - A single-blind randomized controlled trial for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in the gynecology cancer patients.

Overview

Phase: 未知
Intervention: Not specified
Conditions: Patients with gynecologic cancer receiving chemotherapy including carboplatin (that is, TC therapy: carboplatin + paclitaxel)
Sponsor: St. Mariannna University, School of Medicine
Enrollment: 300
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

August 1, 2012

End Date

August 31, 2016

Last Updated

2 years ago

Study Type

Interventional

Sex

Female

Sponsor

•1\. Patients complicated with serious hepatic disorders or renal disorders. 2\. Patients with nausea and vomiting within 24 hours before initiation of cancer chemotherapy. 3\. Patients who used an antiemetic agent within 48 hours before initiation of cancer treatment. 4\. Patients with nausea and vomiting due to causes (brain tumor, digestive passage disorders, active peptic ulcer, brain metastasis, use of opioids, etc.) other than cancer chemotherapy. 5\. Patients with an associated disease, including uncontrolled diabetes, that prevents administration of dexamethasone for three days. 6\. Patients under medication with pimozide. 7\. Patients for whom abdominal radiotherapy is planned. 8\. Patients with a history of vomiting in past chemotherapy. 9\. Patients judged to be inappropriate for the study by the physician in charge.